News

Pipeline – 8/1/22

Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases

— Novel approach to directly target local tissue complement dysregulation resulted in durable and efficacious complement blockade without systemic inhibition in preclinical studies — — Company is planning to evaluate ADX-097 in a Phase 2 clinical trial of complement-mediated renal diseases, with initial data expected by year-end 2024 and topline results in 2025, and a […]

Q32 Bio and Homology Medicines Announce Merger Agreement

–The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders– –Q32 Bio has re-acquired worldwide development and commercial rights […]

Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen

— Q32 Bio now wholly owns development and commercialization rights to the anti-IL-7Rα antibody, currently being evaluated in two Phase 2 trials for atopic dermatitis (AD) and alopecia areata (AA) — — Re-acquisition bolsters Q32 Bio’s autoimmune product portfolio and broadens strategic opportunities — WALTHAM, Mass. – Nov. 16, 2023 — Q32 Bio, a clinical stage biotechnology […]

Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer

Waltham, Mass. – October 24, 2023 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio’s chemistry, manufacturing and control (CMC)-related activities. “We are thrilled to welcome Saul to […]

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

Alopecia areata is the second autoimmune indication being evaluated for bempikibart WALTHAM, Mass., and DUBLIN – September 13, 2023 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study […]